Trevena (NASDAQ:TRVN) Now Covered by StockNews.com

StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN) in a report released on Monday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “neutral” rating and set a $5.00 target price on shares of Trevena in a research note on Thursday, November 14th.

Trevena Stock Up 3.3 %

Shares of NASDAQ TRVN opened at $1.68 on Monday. The firm has a market cap of $1.45 million, a price-to-earnings ratio of -0.04 and a beta of 1.08. Trevena has a 52-week low of $1.13 and a 52-week high of $15.46. The business’s 50 day moving average is $1.72 and its two-hundred day moving average is $2.48.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.